{"preliminary_commentary":{"by_channel":{"x_thread":10,"podcast":5,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05712902\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"WU-KONG6","nct_id":"NCT05712902","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=wu-kong6-nct05712902. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"Daily dose of Sunvozertinib","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":104,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Sunvozertinib","otherNames":["DZD9008"],"type":"DRUG"}],"last_update":"2024-12-30","lead_sponsor":"Dizal Pharmaceuticals","official_title":"A Phase II, Single Arm, Multicenter Study to Evaluate Anti-tumor Activity, Safety, Tolerability and Pharmacokinetics of DZD9008 in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutation","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-10-17","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) according to RECIST 1.1 by an Independent Review Committee (IRC)","timeFrame":"From first dosing until disease progression or intolerable adverse events"}],"references":[{"citation":"Wang M, Fan Y, Sun M, Wang Y, Zhao Y, Jin B, Hu Y, Han Z, Song X, Liu A, Tang K, Ding C, Liang L, Wu L, Gao J, Wang J, Cheng Y, Zhou J, He Y, Dong X, Yao Y, Yu Y, Wang H, Sun S, Huang J, Fang J, Li W, Wang L, Ren X, Zhou C, Hu Y, Zhao D, Yang R, Xu F, Huang Y, Pan Y, Cui J, Xu Y, Yang Z, Shi Y. Sunvozertinib for patients in China with platinum-pretreated locally advanced or metastatic non-small-cell lung cancer and EGFR exon 20 insertion mutation (WU-KONG6): single-arm, open-label, multicentre, phase 2 trial. Lancet Respir Med. 2024 Mar;12(3):217-224. doi: 10.1016/S2213-2600(23)00379-X. Epub 2023 Dec 12.","pmid":"38101437","type":"DERIVED"}],"start_date":{"date":"2021-07-19","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)","url":"https://clinicaltrials.gov/study/NCT05712902"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/wu-kong6-nct05712902"}